Know Cancer

or
forgot password

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study


Phase 2
N/A
N/A
Open (Enrolling)
Both
Neuroblastoma

Thank you

Trial Information

CHP677: I-Metaiodobenzylguanidine (I-MIBG) Therapy for Refractory Neuroblastoma: a Phase II Study

Inclusion Criteria


Inclusion criteria: Refractory neuroblastoma with original diagnosis based on tumor
histopathology or elevated urine VMA with typical tumor cells in the bone marrow.

Type of Study:

Interventional

Study Design:

Primary Purpose: Treatment

Authority:

United States: Federal Government

Study ID:

NCRR-M01RR00240-1748

NCT ID:

NCT00013806

Start Date:

Completion Date:

Related Keywords:

  • Neuroblastoma
  • Relapsed and refractory neuroblastoma
  • Neuroblastoma

Name

Location

Children's Hospital of PhiladelphiaPhiladelphia, Pennsylvania  19104